InsidersTradesSigma
Track the Rafael Holdings, Inc. share price and the full insider trade history of the company, a publicly traded company based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Rafael Holdings, Inc. has published 78 reports. Market capitalisation: €111.8m. The latest transaction was filed on 31 July 2026 (Attribution). Among the most active insiders: Polinsky David. All data is free.
78
Insider Decl.
n/a
Thresholds
€11m
3 ops.
Buy Volume
€124,941
3 ops.
Sell Volume
35Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 22,612 of 29,056 companies
32.3
score / 100
Value15
Quality49
FCF yld-6.0%
Earn yld-26%
EV/EBITDA·
ROE-38%
Gross mgn76%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 31 July 2026
Declarations78 total
54,945 shares@ US$2.73Class B Common Stock, $.01 par value per shareSEC:0001193125-26-328798:0
2,318 shares@ US$1.2750.8% of flowClass B Common Stock, par value $.01 per shareSEC:0001193125-26-121225:0
9,826 shares@ US$1.50250.1% of flowClass B Common Stock, $.01 par value per shareSEC:0001193125-26-110026:0
29,528 shares@ US$1.27100.0% of flowClass B Common Stock, par value $.01 per shareSEC:0001193125-26-031749:0
39,370 shares@ US$1.2719.2% of flowClass B Common Stock, par value $.01 per shareSEC:0001193125-26-028834:0
39,370 shares@ US$1.2767.2% of flowClass B Common Stock, par value $.01 per shareSEC:0001193125-26-028833:0
6,562 shares@ US$1.27100.0% of flowClass B Common Stock, par value $.01 per shareSEC:0001193125-26-028831:0
75,000 shares@ US$1.24850.7% of flowClass B Common Stock, $.01 par value per shareSEC:0001193125-26-014140:0
4,865 shares@ US$1.24851.6% of flowClass B Common Stock, par value $.01 per shareSEC:0001193125-26-014138:0
1,961 shares@ US$1.2850.7% of flowClass B Common Stock, par value $.01 per shareSEC:0001193125-25-330708:0
9,867 shares@ US$1.49750.1% of flowClass B Common Stock, $.01 par value per shareSEC:0001193125-25-321293:0
4,180 shares@ US$1.351.5% of flowClass B Common Stock, par value $.01 per shareSEC:0001193125-25-253316:0
1,284 shares@ US$1.480.5% of flowClass B Common Stock, par value $.01 per shareSEC:0001193125-25-217252:0
1,970 shares@ US$1.490.8% of flowClass B Common Stock, par value $.01 per shareSEC:0001193125-25-210807:0
9,905 shares@ US$1.3450.1% of flowClass B Common Stock, $.01 par value per shareSEC:0001193125-25-205211:0
2,347 shares@ US$1.5951.1% of flowClass B Common Stock, par value $.01 per shareSEC:0000950170-25-089354:0
118,596 shares@ US$2.1081.9% of flowClass B Common Stock, $.01 par value per shareSEC:0000950170-25-087209:0
457,031 shares@ US$1.284.5% of flowClass B Common Stock, $.01 par value per shareSEC:0000950170-25-083855:0
Canonical exit: 3 Sept 2025 (T+90)
76,882 shares@ US$1.2827.3% of flowClass B Common Stock, par value $.01 per shareSEC:0000950170-25-079559:0
35,000 shares@ US$1.2855.9% of flowClass B Common Stock, par value $.01 per shareSEC:0000950170-25-078854:0
27,454 sharesClass B Common Stock, par value $.01 per shareSEC:0000950170-25-057934:0
2,378 shares@ US$1.931.3% of flowClass B Common Stock, par value $.01 per shareSEC:0000950170-25-044471:0
14,814 shares@ US$1.935.4% of flowClass B Common Stock, par value $.01 per shareSEC:0000950170-25-044469:0
60,000 shares@ US$1.95423.5% of flowClass B Common Stock, par value $.01 per shareSEC:0000950170-25-005759:0
50,000 shares@ US$1.954100.0% of flowClass B Common Stock, par value $.01 per shareSEC:0000950170-25-005760:0
25 of 78 declarations
关于 Rafael Holdings, Inc.
Rafael Holdings, Inc. (NYSE: RFL) 是一家在美国上市的公司，在 NYSE/NASDAQ 市场交易，其业务概况明确属于医疗保健和生物技术领域。公司总部位于新泽西州纽瓦克，已从一种更侧重资产持有的结构发展成为一个以开发为重点的生物制药平台，专注于新型疗法，特别是肿瘤学和罕见疾病的机会。其在纽瓦克的公司基地使该集团扎根于美国东北部。（[rafaelholdings.com](https://rafaelholdings.com/?utm_source=openai)） 该公司的运营模式围绕着受控和多数股权医疗保健企业的投资组合构建。在其最新的年度报告中，Rafael Holdings 将自己描述为一家开发药物并持有开发药物和医疗设备的临床和早期阶段公司权益的生物技术公司。其主要候选药物是 Trappsol® Cyclo™，目前正在进行临床试验，以评估其治疗尼曼-匹克病 C1 型（一种罕见的、致命的、进行性遗传疾病）的潜力。Rafael 还持有 LipoMedix Pharmaceuticals、Barer Institute 和 Cornerstone Pharmaceuticals 的权益，并且最近将 Cyclo Therapeutics 纳入其合并投资组合。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1713863/000121390025103549/ea0262395-10k_rafael.htm?utm_source=openai)） 从竞争角度来看，Rafael 最好被视为一家小型生物技术公司，其估值较少受当前商业收入驱动，更多受临床执行、知识产权和资本市场准入驱动。其竞争地位取决于通过开发里程碑推进专业项目、生成有意义的试验数据以及保持灵活性以支持投资组合公司。这是一种典型的开发阶段生物技术发行人的高风险、高回报概况，其中临床结果和监管进展可以实质性地重估股票。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1713863/000121390025103549/ea0262395-10k_rafael.htm?utm_source=openai)） 最近的公司更新集中在截至 2025 年 7 月 31 日的 2025 财年业绩，公司报告的净亏损小于上一年，同时研发支出因新的合并活动而增加。管理层还强调了 Trappsol® Cyclo™ 的持续进展以及向更综合的生物制药企业的更广泛转型。对于讲法语的投资者来说，Rafael Holdings 应被视为 NYSE 上的一家投机性美国医疗保健公司，其主要催化剂来自临床更新、SEC Form 4 内部人申报、融资行动和投资组合层面的交易。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1713863/000121390025103509/ea026292601ex99-1_rafael.htm?utm_source=openai)）
